



ORIGINAL ARTICLE

Acute kidney injury in acute coronary syndromes – An important multifactorial consequence



David Neves^{a,*}, Adriana Belo^b, Ana Filipa Damásio^a, João Carvalho^a,
Ana Rita Santos^a, Bruno Piçarra^a, José Aguiar^a, on behalf of the investigators of the
Portuguese Registry on Acute Coronary Syndromes (ProACS)

^a Cardiology Department, Hospital Espírito Santo, Évora, Portugal

^b Biostatistics Department, Portuguese Society of Cardiology, Lisbon, Portugal

Received 27 February 2016; accepted 28 April 2016

Available online 30 June 2016

KEYWORDS

Acute coronary
syndrome;
Acute kidney injury;
Coronary
angiography;
Percutaneous
coronary
intervention;
Contrast media

Abstract

Introduction: Acute kidney injury (AKI) is a pathological phenomenon with a negative impact on outcomes in different clinical scenarios. Its mechanism in acute coronary syndrome (ACS) is not completely understood, and measures to prevent it are not uniform. We set out to study the incidence, clinical relevance, predictors and possible implications for patient management of AKI in ACS.

Methods: Using data from a multicenter national registry on ACS, we retrospectively analyzed predictors of AKI and its impact on outcomes (in-hospital complications and one-year mortality). All ACS types were included. AKI was defined as an increase in serum creatinine of ≥ 0.3 mg/dl (≥ 26.4 $\mu\text{mol/l}$) and/or by ≥ 1.5 times baseline.

Results: A total of 7808 ACS patients were included in the analysis, 1369 (17.5%) of whom developed AKI. AKI was shown to be an independent predictor of in-hospital major bleeding (odds ratio [OR] 2.09; 95% confidence interval [CI] 1.19-3.64; $p=0.01$), mortality (OR 4.72; 95% CI 2.94-7.56; $p<0.001$) and one-year mortality (hazard ratio 2.01; 95% CI 1.51-2.68; $p<0.001$). The incidence of AKI was associated with older age, history of hypertension, renal failure and stroke/transient ischemic attack, Killip class >1 on admission and left ventricular ejection fraction $<50\%$. Performance of coronary angiography or angioplasty were not associated with AKI. Diuretics during admission were predictors of AKI only in patients in Killip class 1.

Conclusions: AKI is an important finding in ACS, with a significant impact on hard clinical endpoints such as in-hospital and one-year mortality. It is associated with easily identifiable clinical factors and an invasive strategy does not increase its incidence.

© 2016 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.

E-mail address: dcneves25@hotmail.com (D. Neves).

PALAVRAS-CHAVE

Síndrome coronária aguda;
Lesão renal aguda;
Coronariografia;
Angioplastia coronária;
Meios de contraste

Lesão renal aguda em síndromes coronárias agudas – uma consequência multifatorial**Resumo**

Introdução: A lesão renal aguda (LRA) é um fenómeno patológico que acontece em várias situações clínicas. A sua fisiopatologia no contexto de síndrome coronária aguda (SCA) não é completamente conhecida, pelo que as medidas de prevenção não são uniformes. Neste trabalho, estudamos a LRA em relação ao significado clínico, preditores e possíveis implicações para o tratamento no contexto de SCA.

Métodos: Utilizando dados de um registo nacional multicêntrico de SCA, analisámos, retrospectivamente, os preditores de LRA e o impacto na clínica através de complicações intra-hospitalares (IH) e mortalidade a um ano. A LRA foi definida como aumento de creatinina sérica de $\geq 0,3$ mg/dl e/ou 1,5 vezes o seu valor basal durante o internamento.

Resultados: Foram incluídos 7808 doentes com SCA na análise, 1369 (17,5%) dos quais desenvolveram LRA. A LRA revelou ser preditor independente de hemorragia *major* IH (*odds ratio* [OR] 2,09; intervalo de confiança 95% [IC] 1,19-3,64; $p=0,01$), mortalidade IH (OR 4,72; IC 2,94-7,56; $p<0,001$) e mortalidade a um ano (*hazards ratio* 2,01; IC 1,51-2,68; $p<0,001$). A incidência de LRA associa-se ao aumento da idade, hipertensão arterial, insuficiência renal e AVC/AIT, Killip-Kimball (KK) >1 na admissão e fração de ejeção ventricular esquerda $<50\%$. A realização de coronariografia ou angioplastia não se associaram a um aumento de LRA. A utilização de diuréticos foi preditora de LRA apenas em doentes KK 1.

Conclusões: A LRA é um achado importante no contexto de SCA, com impacto clínico significativo, nomeadamente mortalidade intra-hospitalar e a um ano. A LRA associa-se a características clínicas facilmente identificáveis e a estratégia invasiva não aumenta a sua incidência.

© 2016 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.

Introduction

Acute kidney injury (AKI) is a pathological phenomenon that has changed in name and definition in recent years. The initial concepts of acute kidney failure and renal impairment were difficult to compare between studies, so there was a need to standardize a definition of what can be described as an ‘‘acute decline of kidney function as a consequence of a pathological insult’’.

In 2004, the Acute Dialysis Quality Initiative group proposed the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) classification for acute renal failure,¹ which included serum creatinine (SCr) and/or urine output criteria to define three levels of renal dysfunction and two clinical outcomes.

In 2007, the Acute Kidney Injury Network group proposed the term ‘acute kidney injury’ and a new definition for the entire spectrum of acute renal failure, based on the previous RIFLE criteria.² It included three stages of AKI, also taking into account SCr and/or urine output.

The latest definition was published in 2012 by the Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group.³ It combines the previous definitions: AKI is present if SCr increases by ≥ 0.3 mg/dl (≥ 26.5 $\mu\text{mol/l}$) in 48 hours or by ≥ 1.5 times baseline within seven days, or if urine volume is <0.5 ml/kg per hour for six hours.

These criteria were largely derived from critically ill patients in intensive care units, with AKI of varying etiologies, and KDIGO appears to be a better predictor of in-hospital mortality than RIFLE.⁴ Understanding of AKI in acute coronary syndrome (ACS) is improving, but is still

limited. This study aimed to determine the incidence of AKI in ACS patients, to assess its impact on clinical outcomes, and to determine its predictors.

Methods**Study population and data management**

This was a retrospective study derived from the Portuguese Registry on Acute Coronary Syndromes (ProACS). Data are collected at a national level from all participating centers and entered into a dedicated web-based platform by the attending physician or other designated person at the time of discharge and at one-year follow-up. Information is recorded on demographics, clinical profile, clinical presentation, laboratory and imaging results, interventions, medication and in-hospital complications (reinfarction, congestive heart failure, shock, atrial fibrillation, mechanical complication, atrioventricular block, sustained ventricular tachycardia, cardiac arrest, stroke, major bleeding and death). Patients with all types of ACS, namely unstable angina, non-ST elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI), are included. Patients on dialysis are excluded. The period from October 1, 2010 to March 23, 2015 was analyzed, in which a total of 11 812 patients were included.

AKI was defined as an increase in SCr of ≥ 0.3 mg/dl (≥ 26.4 $\mu\text{mol/l}$) and/or by ≥ 1.5 times baseline during the admission period. Chronic renal failure was defined as serum creatinine >2.0 mg/dl prior to admission or a history of

renal transplant. Major bleeding included severe or life-threatening bleeding, as defined by the GUSTO criteria.⁵

Statistical analysis

Baseline characteristics were compared between patient groups (with and without AKI), using Student's *t* tests or Mann-Whitney *U* tests for continuous variables and the chi-square test or Fisher's exact test for categorical variables, as appropriate. Continuous variables were expressed as mean \pm standard deviation (SD) or median (Q1-Q3), and dichotomous variables as percentages.

A multivariate logistic regression analysis was performed to assess independent predictors of AKI and the influence of AKI on in-hospital mortality and complications. A Cox proportional hazards model was used to assess the influence of AKI on cumulative mortality at one year. Odds ratios (OR) and hazard ratios (HR) were calculated with 95% confidence intervals.

IBM SPSS Statistics version 19 was used for the statistical analysis and a *p* value of <0.05 was considered statistically significant.

Results

Baseline characteristics

The baseline characteristics of the study population are summarized in Table 1, which also shows univariate associations with development of AKI. A total of 7808 patients were included in the analysis, after confirmation of availability of complete patient data required for this study. About three-quarters of the patients were male. AKI was associated with older age and higher prevalence of hypertension and diabetes. Interestingly, AKI patients were less frequently smokers and less frequently underwent coronary angiography and percutaneous coronary intervention (PCI). To assess the true influence of these clinical and procedural variables on development of AKI, a multivariate logistic regression analysis was performed.

Predictors of acute kidney injury

The following characteristics were included in the logistic regression analysis: demographics, ACS type, risk factors and comorbidities, Killip class on admission, performance of angiography, angiography results, performance of percutaneous coronary intervention (PCI), left ventricular ejection fraction (LVEF), and previous medication and medication during admission (angiotensin converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs] and diuretics). Results are summarized in Table 2. Older age and history of hypertension, renal failure and stroke/transient ischemic attack were identified as independent predictors of AKI, as was Killip class >1 on admission and LVEF <50%. The performance of angiography and/or PCI did not increase the incidence of AKI. Statins and ACEIs or ARBs did not show a statistically significant independent effect on the development of AKI, although a tendency towards a protective effect was noted for both drug types. Diuretics during the




Figure 1 Kaplan-Meier survival curve.

admission period were shown to be independent predictors of AKI. However, a strong interaction between diuretics and Killip class was noted, i.e. diuretics were independent predictors of AKI if Killip class on admission was I (OR 2.92 [2.46-3.47]) but not if it was II-IV (OR 1.32 [0.93-1.88]).

Impact of acute kidney injury on outcomes

AKI was associated with increases in in-hospital major bleeding, shock and mechanical complications. Of all in-hospital complications included in the study, after multivariate regression analysis only major bleeding was independently predicted by AKI, with OR 2.09 (95% CI 1.19-3.64) (*p*=0.01). AKI was also an independent predictor of mortality, both in-hospital (Table 3), and at one-year follow-up (Figure 1, Supplementary Table 1) (HR 2.01; 95% CI 1.51-2.68; *p*<0.001). The type of ACS does not seem to significantly affect the impact of AKI on these outcomes. LVEF is still an excellent tool for risk stratification, for both in-hospital and one-year mortality.

Discussion

The major findings of this study are that AKI is an independent predictor of major bleeding and mortality (both in-hospital and at one year) and that it is independently associated with easily identifiable clinical variables, such as Killip class >1 at admission, previous renal dysfunction, older age and depressed LVEF. AKI patients tend to be older and more often hypertensive and diabetic, conditions known to affect renal functional reserve, and also tend to have more complex coronary artery disease.

STEMI patients seem to be at greatest risk for developing AKI. This finding is to be expected, since they represent patients with ACS of greatest hemodynamic impact and/or with lowest hemodynamic and renal functional reserve. Interestingly, diuretic use was also an independent predictor of AKI, but only in Killip class 1 patients, not in Killip class >1, which may be a reflection of its benefit only in the presence of marked fluid overload. Statins did not seem

Table 1 Baseline and admission characteristics of the study population.

Variable	Total (n=7808)	No AKI (n=6439)	AKI (n=1369)	p
Mean age (years)	66±13	65±13	73±12	<0.001
Male (%)	72.1	73.3	66.5	<0.001
BMI (kg/m ²)	27.4±4.3	27.4±4.3	27.4±4.5	0.954
Patient delay (min) ^a	157 [80; 340]	150 [78; 321]	194.5 [93.5; 440.5]	<0.001
Smoking (%)	27.4	30.0	15.0	<0.001
Hypertension (%)	69.7	67.5	80.0	<0.001
Diabetes (%)	30.3	28.8	37.5	<0.001
Dyslipidemia (%)	58.5	58.5	58.2	0.856
Previous MI (%)	20.5	19.9	23.6	0.002
Previous PCI (%)	14.4	14.5	13.8	0.529
Previous CABG (%)	4.9	4.9	4.7	0.691
Previous renal failure (%)	4.8	3.2	12.8	<0.001
Previous PAD (%)	5.5	4.8	8.7	<0.001
ACS type				
STEMI (%)	41.2	41.1	41.7	0.674
– anterior (%)	48.5	46.6	57.3	<0.001
– inferior (%)	50.4	52.4	41.0	<0.001
New LBBB (%)	1.2	1.0	1.8	0.137
NSTEMI (%)	48.9	49.2	47.6	0.282
UA (%)	6.0	6.5	3.2	<0.001
Physical examination on presentation				
HR (bpm)	78±20	77±19	82±23	<0.001
Systolic BP (mmHg)	139±29	139±29	139±31	0.794
Diastolic BP (mmHg)	79±17	79±17	78±18	0.015
Killip class II-IV	15.2	11.0	34.8	<0.001
BNP (pg/ml)	170.5 [67; 643]	138 [54; 334]	529 [211; 1140]	<0.001
Coronary angiography (%)	87.3	88.7	80.3	<0.001
Extent of CAD (%)^b				
0 vessels	6.6	7.0	4.4	0.002
1-vessel	42.8	44.3	34.9	<0.001
2-vessel	28.8	28.2	32.2	0.009
3-vessel	21.8	20.5	28.5	<0.001
PCI performed (%)	65.4	66.9	58.2	<0.001
LVEF <50% (%)	36.4	32.5	55.0	<0.001
In-hospital medication				
ACEIs/ARBs (%)	87.1	87.9	83.2	<0.001
Diuretics (%)	30.5	23.8	62.0	<0.001
Statins (%)	95.5	95.9	93.7	<0.001
In-hospital complications				
Reinfarction (%)	1.0	1.1	1.0	0.737
Congestive heart failure (%)	10.6	10.8	9.2	0.085
Atrial fibrillation (%)	3.5	3.4	4.0	0.266
Stroke (%)	0.7	0.6	0.7	0.695
Major bleeding (%)	1.3	1.0	2.4	<0.001
AV block (%)	2.6	2.6	2.5	0.877
Sustained VT (%)	1.3	1.2	1.8	0.053

ACEIs: angiotensin-converting enzyme inhibitors; ACS: acute coronary syndrome; AKI: acute kidney injury; ARBs: angiotensin receptor blockers; AV: atrioventricular; BMI: body mass index; BNP: brain-type natriuretic peptide, expressed in pg/ml as median [1st quartile; 3rd quartile]; BP: blood pressure; CABG: coronary artery bypass grafting; CAD: coronary artery disease; HR: heart rate; LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; OR: odds ratio, expressed as OR (95% confidence interval); PAD: peripheral arterial disease; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction; VT: ventricular tachycardia.

^a Defined as time from pain onset to first medical contact, and expressed in min as median [1st quartile; 3rd quartile].

^b Defined as number of main coronary arteries (left main [LM], left anterior descending [LAD], left circumflex [LCX], right coronary [RCA]) with ≥50% stenosis: 1-vessel=LAD, LCX or CD; 2-vessel: LM, LM+LAD, LM+LCX, LM+LAD+LCX, DA+CX, LAD+RCA or LCX+RCA; 3-vessel: LAD+LCX+RCA, LM+RCA, LM+LAD+RCA, LM+LCX+RCA or LM+LAD+LCX+RCA.

Table 2 Multivariate logistic regression assessing predictors of development of acute kidney injury.

Predictor	Beta	SE	p	OR (95% CI)
Age	0.029	0.003	<0.001	1.03 (1.02-1.04)
Previous renal failure	0.834	0.131	<0.001	2.30 (1.78-2.98)
Hypertension	0.275	0.089	0.002	1.32 (1.11-1.57)
Previous stroke/TIA	0.238	0.112	0.034	1.27 (1.02-1.58)
Killip class on presentation >1				
<i>Diuretics during admission</i>	0.361	0.097	<0.001	1.43 (1.19-1.74)
<i>No diuretics during admission</i>	1.154	0.172	<0.001	3.17 (2.26-4.45)
Drugs during admission period:				
Diuretics				
Killip class 1	1.072	0.088	<0.001	2.92 (2.46-3.47)
Killip class >1	0.279	0.179	0.119	1.32 (0.93-1.88)
ACEIs/ARBs	-0.119	0.104	0.251	0.89 (0.72-1.09)
Statins	-0.180	0.156	0.248	0.83 (0.61-1.13)
Angiography	-0.501	0.189	0.008	0.61 (0.42-0.88)
PCI	-0.037	0.095	0.698	0.96 (0.80-1.16)
LVEF <50%	0.329	0.076	<0.001	1.39 (1.20-1.61)

ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CI: confidence interval; LVEF: left ventricular ejection fraction; OR: odds ratio; PCI: percutaneous coronary intervention; SE: standard error; TIA: transient ischemic attack.

to protect against AKI, although these drugs at high doses have been shown to have an important role in preventing AKI.⁶⁻⁸ ACEIs/ARBs also failed to demonstrate a significant protective effect.

Also of note, the performance of angiography and angioplasty were not associated with increased development of AKI, despite the associated use of nephrotoxic contrast agents. In this context, it could be postulated that the hemodynamic benefit of revascularization may outweigh the deleterious effect of contrast use. Increasingly used prophylactic measures for AKI, such as vigorous hydration and

high-dose statins, may also have played a part in these results.

Our findings are generally in line with those of previously published studies in several respects. The negative impact of AKI on short- and long-term outcomes of patients undergoing PCI has been demonstrated by several groups, particularly in terms of in-hospital and long-term mortality.⁹⁻¹⁴ Similarly, in ACS patients development of AKI and its severity are associated with a progressively higher risk of in-hospital morbidity and mortality.¹⁵ The commonly used scores for AKI diagnosis and staging have also been tested in ACS, and the

Table 3 Multivariate logistic regression assessing predictors of in-hospital mortality.

Predictor	Beta	SE	p	OR (95% CI)
AKI	1.551	0.241	<0.001	4.72 (2.94-7.56)
Female	0.598	0.238	0.012	1.82 (1.14-2.90)
Age	0.046	0.011	<0.001	1.05 (1.02-1.07)
STEMI	1.060	0.256	<0.001	2.89 (1.75-4.76)
Valve disease	1.654	0.379	<0.001	5.23 (2.49-10.98)
PAD	0.988	0.382	0.010	2.68 (1.27-5.68)
Killip class on presentation				
II	0.481	0.282	0.088	1.62 (0.93-2.81)
III	0.734	0.388	0.058	2.08 (0.97-4.45)
IV	2.228	0.444	<0.001	9.28 (3.88-22.17)
Multivessel disease	0.612	0.249	0.014	1.84 (1.13-3.00)
LVEF				
Mildly depressed	0.176	0.371	0.635	1.19 (0.58-2.47)
Moderately depressed	1.344	0.309	<0.001	3.84 (2.09-7.03)
Severely depressed	2.378	0.328	<0.001	10.78 (5.67-20.50)

AKI: acute kidney injury; CI: confidence interval; LVEF: left ventricular ejection fraction; OR: odds ratio; PAD: peripheral arterial disease; SE: standard error; STEMI: ST-elevation myocardial infarction.

KDIGO criteria appear to be better than RIFLE for predicting early and late mortality in myocardial infarction (MI).¹⁶

In the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) registry,¹⁷ in which most patients had ACS (72%), both cardiovascular and renal events also increased with the presence and severity of AKI. AKI in the setting of ACS is frequently interpreted as contrast-induced, and in this context it has been shown to be a predictor of mortality in-hospital and in follow-up (median 94 months).¹³

The importance of contrast for the development of AKI in ACS is still the subject of debate. Other mechanisms, with both prerenal and renal pathophysiology, have been proposed, such as the hemodynamic impact of the ACS, bleeding complications, atheroembolic phenomena, drug toxicity and acute hyperglycemia.¹⁸ BNP levels have been shown to be associated with the development of AKI, possibly reflecting both cardiac and renal impairment in the context of ACS.¹⁹ Radial access has recently been shown in a meta-analysis²⁰ to be significantly less associated with AKI than femoral access, possibly related to reduced bleeding complications. The AKI-MATRIX sub-study²¹ will probably add important information in this regard. Several groups have recently developed scores to predict the development of AKI after PCI.^{22–24} Interestingly, they are very robust, despite being based on preprocedural data only, and in all of them AKI appears to be more frequent in ACS, including MI, than in stable patients. This suggests there are important mechanisms of AKI in ACS patients, other than contrast use or volume. In this regard, a recent study by McDonald et al. suggests that iodinated contrast use is not associated with development of AKI in patients undergoing CT.²⁵

Although it is probably not the main mechanism, there is still evidence of the deleterious effect of contrast material on renal function in ACS.²⁶ An early invasive strategy in NSTEMI has been reported to be associated with a small increase in AKI, but not dialysis or progression to end-stage kidney disease, and it still reduced long-term mortality.²⁷ In primary PCI, contrast volume is still an important determinant of AKI,²⁸ regardless of preprocedural risk,²⁹ which supports the idea of keeping contrast use to a reasonable minimum.³⁰

Study limitations

The main limitations of this study derive from its retrospective design, which limits available data. Data on preventive measures for AKI were not available, nor on the type and volume of contrast used. However, pooling all invasively treated patients together did not show an increased incidence of AKI, regardless of the contrast volume used, which is assumed to have been kept to a minimum as standard practice. Some AKI cases may have been missed, because SCr on admission may not reflect true baseline levels, i.e. AKI might already be ongoing, since time from symptom onset to admission was variable. It would also be interesting to study AKI with other biomarkers, like NGAL,^{31,32} cystatin C³³ and KIM-1,³⁴ which are potentially more accurate indicators of AKI than creatinine. Information on statin doses was not available, which may be responsible for the absence of a protective effect of statins in our results.

Conclusions

AKI is an important finding in the ACS context, with impact on hard clinical endpoints, such as major bleeding and mortality. Easily identifiable markers of vulnerable patients are Killip class >1 at admission, previous renal dysfunction, older age and depressed LVEF. Care should be taken when using diuretics, which may be deleterious in the absence of fluid overload. Mechanisms other than contrast toxicity are likely to have an important role. Invasive management of ACS does not seem to increase AKI. However, keeping contrast volume to a reasonable minimum is still advisable.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgments

The authors would like to thank all contributors from all participating centers in ProACS, as well as the Portuguese Society of Cardiology for this ever-growing initiative.

Appendix A. Supplementary material

Supplementary material associated with this article can be found in the online version at [doi:10.1016/j.repc.2016.04.008](https://doi.org/10.1016/j.repc.2016.04.008).

References

1. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care*. 2004;8:R204–12.
2. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care*. 2007;11:R31.
3. Kellum JA, Lameire N, Aspelin P, et al. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl*. 2012;2:1–138.
4. Luo X, Jiang L, Du B, et al. A comparison of different diagnostic criteria of acute kidney injury in critically ill patients. *Crit Care*. 2014;18:R144.
5. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med*. 1993;329:673–82.

6. Thompson K, Razi R, Lee MS, et al. Statin use prior to angiography for the prevention of contrast-induced acute kidney injury: a meta-analysis of 19 randomised trials. *EuroIntervention*. 2015;11:20140626–31, http://dx.doi.org/10.4244/EIJY15M05_03 [Epub ahead of print].
7. Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). *J Am Coll Cardiol*. 2014;63:71–9.
8. Marenzi G, Cosentino N, Werba JP, et al. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. *Int J Cardiol*. 2015;183:47–53.
9. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. *J Am Coll Cardiol*. 2000;36:1542–8.
10. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation*. 2002;105:2259–64.
11. Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. *J Am Soc Nephrol*. 2006;17:2871–7.
12. Watabe H, Sato A, Hoshi T, et al. Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. *Int J Cardiol*. 2014;174:57–63. Elsevier Ireland Ltd.
13. Farhan S, Vogel B, Tentzeris I, et al. Contrast induced acute kidney injury in acute coronary syndrome patients: a single centre experience. *Eur Hear J Acute Cardiovasc Care*. 2015.
14. Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. *JACC Cardiovasc Interv*. 2014;7:1–9.
15. Marenzi G, Cabiati A, Bertoli SV, et al. Incidence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. *Am J Cardiol*. 2013;111:816–22. Elsevier Inc.
16. Rodrigues FB, Bruetto RG, Torres US, et al. Incidence and mortality of acute kidney injury after myocardial infarction: a comparison between KDIGO and RIFLE criteria. *PLoS ONE*. 2013;8:1–8.
17. James MT, Ghali WA, Knudtson ML, et al. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. *Circulation*. 2011;123:409–16.
18. Marenzi G, De Metrio M, Rubino M, et al. Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. *Am Heart J*. 2010;160:1170–7. Mosby, Inc.
19. Moltrasio M, Cabiati A, Milazzo V, et al. B-type natriuretic peptide and risk of acute kidney injury in patients hospitalized with acute coronary syndromes. *Crit Care Med*. 2014;42:619–24.
20. Andò G, Costa F, Boretti I, et al. Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: a meta-analysis of 22,108 patients. *Int J Cardiol*. 2015;179:309–11. Elsevier.
21. Andò G, Cortese B, Frigoli E, et al. Acute kidney injury after percutaneous coronary intervention: rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study. *Catheter Cardiovasc Interv*. 2015;86:950–7.
22. Inohara T, Kohsaka S, Abe T, et al. Development and validation of a pre-percutaneous coronary intervention risk model of contrast-induced acute kidney injury with an integer scoring system. *Am J Cardiol*. 2015;115:1636–42. Elsevier Inc.
23. Tsai TT, Patel UD, Chang TI, et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry. *J Am Heart Assoc*. 2014;3:e001380-e001380.
24. Gurm HS, Seth M, Kooiman J, et al. A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol*. 2013;61:2242–8.
25. McDonald RJR, McDonald JSJ, Carter RER, et al. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. *Radiology*. 2014;273.
26. de Sousa CS, Pedro MM, Pinto FJ. Nefropatia de contraste após intervenção coronária percutânea. A propósito de um caso. *Rev Port Cardiol*. 2009;28:309–21.
27. James MT, Tonelli M, Ghali WA, et al. Renal outcomes associated with invasive versus conservative management of acute coronary syndrome: propensity matched cohort study. *BMJ*. 2013;347:f4151.
28. Marenzi G. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. *Ann Intern Med*. 2009;150:170.
29. Andò G, de Gregorio C, Morabito G, et al. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention. *Circ Cardiovasc Interv*. 2014:465–73.
30. Andò G, Trio O, de Gregorio C. Risk stratification of contrast-induced acute kidney injury after percutaneous coronary intervention: should we finally get rid of procedural variables? *Am J Cardiol*. 2015:9149. Elsevier Inc.
31. Mårtensson J, Bellomo R. The rise and fall of NGAL in acute kidney injury. *Blood Purif*. 2014;37:304–10.
32. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. *Biomark Med*. 2010;4:265–80.
33. Soto K, Coelho S, Rodrigues B, et al. Cystatin C as a marker of acute kidney injury in the emergency department. *Clin J Am Soc Nephrol*. 2010;5:1745–54.
34. Sabbisetti VS, Waikar SS, Antoine DJ, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. *J Am Soc Nephrol*. 2014;25:2177–86.